Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura T Morton

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Current Opinion in Rheumatology|November 25, 2015
Genetics of Behçet's diseaseLaura T Morton, Deva Situnayake, Graham R Wallace
Oncotarget|May 1, 2018
A Jurkat 76 based triple parameter reporter system to evaluate TCR functions and adoptive T cell strategiesSandra Rosskopf, Judith Leitner, Wolfgang Paster, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 23, 2019
Simultaneous Deletion of Endogenous TCRαβ for TCR Gene Therapy Creates an Improved and Safe Cellular TherapeuticLaura T Morton, Rogier M Reijmers, Anne K Wouters, et al.
Frontiers in Immunology|May 1, 2024
Self-sufficient primary natural killer cells engineered to express T cell receptors and interleukin-15 exhibit improved effector function and persistenceEls P van Hees, Laura T Morton, Dennis F G Remst, et al.
The Journal of Experimental Medicine|April 10, 2013
MHC II tetramers visualize human CD4+ T cell responses to Epstein-Barr virus infection and demonstrate atypical kinetics of the nuclear antigen EBNA1 responseHeather M Long, Odette L Chagoury, Alison M Leese, et al.
Nature Cancer|April 15, 2024
Author Correction: Breaking the performance ceiling for neoantigen immunogenicity predictionHugh O'Brien, Max Salm, Laura T Morton, et al.
Journal for Immunotherapy of Cancer|March 15, 2022
T cell receptor engineering of primary NK cells to therapeutically target tumors and tumor immune evasionLaura T Morton, Tassilo L A Wachsmann, Miranda H Meeuwsen, et al.
Nature Cancer|December 15, 2023
Breaking the performance ceiling for neoantigen immunogenicity predictionHugh O'Brien, Max Salm, Laura T Morton, et al.
The Journal of Infectious Diseases|August 19, 2020
Identification of Functional HLA-A*01:01-Restricted Epstein-Barr Latent Membrane Protein 2-Specific T-Cell ReceptorsWesley Huisman, Ilse Gille, Lieve E van der Maarel, et al.
Molecular Therapy. Methods & Clinical Development|February 23, 2023
Human iPSC-derived preclinical models to identify toxicity of tumor-specific T cells with clinical potentialRosa A van Amerongen, Laura T Morton, Umesh G Chaudhari, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Current Opinion in Rheumatology|November 25, 2015
Genetics of Behçet's diseaseLaura T Morton, Deva Situnayake, Graham R Wallace
Oncotarget|May 1, 2018
A Jurkat 76 based triple parameter reporter system to evaluate TCR functions and adoptive T cell strategiesSandra Rosskopf, Judith Leitner, Wolfgang Paster, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 23, 2019
Simultaneous Deletion of Endogenous TCRαβ for TCR Gene Therapy Creates an Improved and Safe Cellular TherapeuticLaura T Morton, Rogier M Reijmers, Anne K Wouters, et al.
Frontiers in Immunology|May 1, 2024
Self-sufficient primary natural killer cells engineered to express T cell receptors and interleukin-15 exhibit improved effector function and persistenceEls P van Hees, Laura T Morton, Dennis F G Remst, et al.
The Journal of Experimental Medicine|April 10, 2013
MHC II tetramers visualize human CD4+ T cell responses to Epstein-Barr virus infection and demonstrate atypical kinetics of the nuclear antigen EBNA1 responseHeather M Long, Odette L Chagoury, Alison M Leese, et al.
Nature Cancer|April 15, 2024
Author Correction: Breaking the performance ceiling for neoantigen immunogenicity predictionHugh O'Brien, Max Salm, Laura T Morton, et al.
Journal for Immunotherapy of Cancer|March 15, 2022
T cell receptor engineering of primary NK cells to therapeutically target tumors and tumor immune evasionLaura T Morton, Tassilo L A Wachsmann, Miranda H Meeuwsen, et al.
Nature Cancer|December 15, 2023
Breaking the performance ceiling for neoantigen immunogenicity predictionHugh O'Brien, Max Salm, Laura T Morton, et al.
The Journal of Infectious Diseases|August 19, 2020
Identification of Functional HLA-A*01:01-Restricted Epstein-Barr Latent Membrane Protein 2-Specific T-Cell ReceptorsWesley Huisman, Ilse Gille, Lieve E van der Maarel, et al.
Molecular Therapy. Methods & Clinical Development|February 23, 2023
Human iPSC-derived preclinical models to identify toxicity of tumor-specific T cells with clinical potentialRosa A van Amerongen, Laura T Morton, Umesh G Chaudhari, et al.
Pageof 2